Venture Capital

Intervenn Biosciences Raises $34M To Commercialize Glycoproteomic Ldt For Ovarian Cancer And Immuno-oncology; Taps John Leite, Ph.d., As Chief Business Officer | Business Wire

by businesswire.com posted 1year ago 219 views
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #AI--InterVenn Biosciences today announced it has raised $34M in a Series B fundraising. The latest round was led by Anzu Partners with full participation of Genoa Ventures, Amplify Partners, and True Ventures; Xeraya Capital and the Ojjeh Family joined the syndicate as well. Funds will be used to commercialize the company’s High-Throughput-Glycoproteomic powered diagnostic for ovarian cancer; to service increasing partnership platform demand; and to acc.

In this article